ECSP17038999A - 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 - Google Patents

4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Info

Publication number
ECSP17038999A
ECSP17038999A ECIEPI201738999A ECPI201738999A ECSP17038999A EC SP17038999 A ECSP17038999 A EC SP17038999A EC IEPI201738999 A ECIEPI201738999 A EC IEPI201738999A EC PI201738999 A ECPI201738999 A EC PI201738999A EC SP17038999 A ECSP17038999 A EC SP17038999A
Authority
EC
Ecuador
Prior art keywords
gpr139
benzotriazines
modulators
dihydro
oxo
Prior art date
Application number
ECIEPI201738999A
Other languages
English (en)
Spanish (es)
Inventor
Holly Reichard
Stephen Hitchcock
Betty Lam
Holger Monenschein
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP17038999A publication Critical patent/ECSP17038999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECIEPI201738999A 2014-11-20 2017-06-20 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 ECSP17038999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
ECSP17038999A true ECSP17038999A (es) 2017-10-31

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201738999A ECSP17038999A (es) 2014-11-20 2017-06-20 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (enExample)
EP (2) EP3221298B1 (enExample)
JP (2) JP6637501B2 (enExample)
KR (1) KR102582021B1 (enExample)
CN (2) CN112062730B (enExample)
AU (1) AU2015349866B2 (enExample)
CA (1) CA2968242C (enExample)
CL (1) CL2017001292A1 (enExample)
CO (1) CO2017005959A2 (enExample)
CR (1) CR20170275A (enExample)
CY (2) CY1122613T1 (enExample)
DK (2) DK3221298T3 (enExample)
DO (1) DOP2017000120A (enExample)
EA (1) EA033728B1 (enExample)
EC (1) ECSP17038999A (enExample)
ES (2) ES2734735T3 (enExample)
GE (2) GEP20196961B (enExample)
HR (2) HRP20212009T1 (enExample)
HU (2) HUE057451T2 (enExample)
IL (1) IL252311B (enExample)
JO (1) JO3719B1 (enExample)
LT (2) LT3221298T (enExample)
MA (1) MA40993B1 (enExample)
MD (1) MD3221298T2 (enExample)
MX (1) MX378158B (enExample)
MY (1) MY187423A (enExample)
NZ (1) NZ732208A (enExample)
PE (1) PE20170899A1 (enExample)
PH (1) PH12017500920B1 (enExample)
PL (2) PL3536324T3 (enExample)
PT (2) PT3221298T (enExample)
RS (2) RS59078B1 (enExample)
SG (1) SG11201704002UA (enExample)
SI (2) SI3221298T1 (enExample)
SM (2) SMT201900355T1 (enExample)
TN (1) TN2017000196A1 (enExample)
TW (1) TWI684590B (enExample)
UA (1) UA120375C2 (enExample)
UY (1) UY36406A (enExample)
WO (1) WO2016081736A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en) 2018-10-16 2024-07-23 The University Of Florida Research Foundation, Incorporated Methods related to opioid therapeutics
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
TWI873185B (zh) * 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
JP7697974B2 (ja) * 2020-05-08 2025-06-24 武田薬品工業株式会社 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
US20230310441A1 (en) * 2020-09-21 2023-10-05 Takeda Pharmaceutical Company Treatment for schizophrenia
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
CN117815217B (zh) * 2023-12-29 2026-07-10 郑州大学第三附属医院(河南省妇幼保健院) 一种苯甲酰胺衍生物改善认知功能障碍的用途
WO2025162441A1 (zh) * 2024-02-02 2025-08-07 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用
CN121159462A (zh) * 2025-11-19 2025-12-19 杭州市第七人民医院(杭州市心理危机研究与干预中心) 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0257102B1 (en) 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
ATE108791T1 (de) * 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
EP1651643A4 (en) 2003-07-31 2008-10-08 Irm Llc BICYCLIC COMPOUNDS AND COMPOSITIONS USED AS PDF INHIBITORS
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2139895A1 (en) * 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
EP2968240A2 (en) * 2013-03-14 2016-01-20 Janssen Pharmaceutica, N.V. Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
KR20170084324A (ko) 2017-07-19
SMT202200142T1 (it) 2022-05-12
JP2020063285A (ja) 2020-04-23
HRP20212009T1 (hr) 2022-04-01
US20160145218A1 (en) 2016-05-26
US20170348319A1 (en) 2017-12-07
BR112017010311A2 (pt) 2017-12-26
MX2017006448A (es) 2017-09-12
NZ732208A (en) 2023-02-24
CO2017005959A2 (es) 2017-10-20
TW201625566A (zh) 2016-07-16
IL252311B (en) 2020-07-30
CN107108531A (zh) 2017-08-29
AU2015349866B2 (en) 2020-12-03
CA2968242C (en) 2022-11-08
CY1124929T1 (el) 2023-01-05
DK3536324T3 (da) 2021-10-25
CA2968242A1 (en) 2016-05-26
MD3221298T2 (ro) 2019-10-31
TN2017000196A1 (en) 2018-10-19
CL2017001292A1 (es) 2018-02-16
US10159677B2 (en) 2018-12-25
US10561662B2 (en) 2020-02-18
US20190070187A1 (en) 2019-03-07
MX378158B (es) 2025-03-10
RS59078B1 (sr) 2019-09-30
PH12017500920A1 (en) 2017-11-20
PE20170899A1 (es) 2017-07-12
US11173161B2 (en) 2021-11-16
EA033728B1 (ru) 2019-11-20
PL3221298T3 (pl) 2019-10-31
CN112062730B (zh) 2023-09-29
IL252311A0 (en) 2017-07-31
EP3221298B1 (en) 2019-04-03
CN107108531B (zh) 2020-10-20
GEAP201814515A (en) 2018-12-10
LT3221298T (lt) 2019-08-12
PT3536324T (pt) 2021-11-10
ES2734735T3 (es) 2019-12-11
UY36406A (es) 2016-06-30
JO3719B1 (ar) 2021-01-31
HUE044145T2 (hu) 2019-09-30
JP6637501B2 (ja) 2020-01-29
AU2015349866A1 (en) 2017-06-15
MY187423A (en) 2021-09-22
CY1122613T1 (el) 2021-05-05
DOP2017000120A (es) 2017-06-15
KR102582021B1 (ko) 2023-09-22
EP3536324B1 (en) 2021-10-06
HRP20191003T1 (hr) 2019-08-23
PT3221298T (pt) 2019-06-28
MA40993A (fr) 2017-09-27
US9556130B2 (en) 2017-01-31
SI3221298T1 (sl) 2019-10-30
GEP20196961B (en) 2019-03-25
US20170095480A1 (en) 2017-04-06
ES2897545T3 (es) 2022-03-01
HUE057451T2 (hu) 2022-05-28
LT3536324T (lt) 2021-12-10
DK3221298T3 (da) 2019-06-24
JP6918088B2 (ja) 2021-08-11
SMT201900355T1 (it) 2019-07-11
CN112062730A (zh) 2020-12-11
US9770450B2 (en) 2017-09-26
UA120375C2 (uk) 2019-11-25
TWI684590B (zh) 2020-02-11
SG11201704002UA (en) 2017-06-29
EA201791096A1 (ru) 2017-11-30
JP2017535559A (ja) 2017-11-30
PH12017500920B1 (en) 2017-11-20
PL3536324T3 (pl) 2022-02-07
WO2016081736A1 (en) 2016-05-26
US20200129518A1 (en) 2020-04-30
RS62563B1 (sr) 2021-12-31
MA40993B1 (fr) 2019-07-31
SI3536324T1 (sl) 2021-12-31
EP3221298A1 (en) 2017-09-27
EP3536324A1 (en) 2019-09-11
CR20170275A (es) 2017-10-30

Similar Documents

Publication Publication Date Title
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2017000054A1 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
JOP20190175A1 (ar) مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)
MX2017014375A (es) Moduladores del ccr2.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CL2016002515A1 (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1.
MX2017009514A (es) Moduladores de los receptores a3 de adenosina.
CU20180044A7 (es) Derivados novedosos de diamino piridina
SV2016005282A (es) Nuevos compuestos